Peptides in Breast Cancer Therapy: From Mechanisms to Emerging Drug Delivery and Immunotherapy Strategies DOI

Elmira Alaei,

Farid Hashemi,

Najma Farahani

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155946 - 155946

Published: March 1, 2025

Language: Английский

Peptide-driven strategies against lung cancer DOI

Vijayshree S Karankar,

Saurabh Awasthi, Nidhi Srivastava

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123453 - 123453

Published: Feb. 1, 2025

Language: Английский

Citations

0
BIO-NANOMATERIALS: PROMISING ANTICANCER PROPERTIES AND TREATMENT STRATEGIES DOI Creative Commons

Elias E. Elemike,

Innocent Chukwujekwu Onunkwo,

Odiri Ughumiakpor

et al.

Nano TransMed, Journal Year: 2025, Volume and Issue: 4, P. 100076 - 100076

Published: Feb. 21, 2025

Language: Английский

Citations

0
Advances and future directions in radiopharmaceutical delivery for cancer treatment DOI
Sikander Ailawadhi,

Deanna Pafundi,

Jennifer Peterson

et al.

Expert Review of Anticancer Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Targeted radiopharmaceutical therapies (RPTs) have emerged as a promising approach for the precise treatment of various cancers. Delivering ionizing radiation directly to cancer cells while sparing surrounding healthy tissue, radiopharmaceuticals offer enhanced efficacy and reduced toxicity compared conventional external beam therapy (i.e. photons electrons). In current era personalized care, appropriate choice RPTs clinical condition specific patient's care needs be better understood. Several available RPT agents with their respective applicability along rapidly ongoing research in this field now given ability lend themselves medicine focus. This review provides an overview recent advancements RPT, including nuclide selection development, molecular targeting strategies, applications. We discuss underlying principles, challenges, opportunities future development. Furthermore, we explore emerging technologies directions field, highlighting potential impact on care.

Language: Английский

Citations

0
Development of Novel Peptides That Target the Ninjurin 1 and 2 Pathways to Inhibit Cell Growth and Survival via p53 DOI Creative Commons
Jin Zhang,

Xiangmudong Kong,

Xinbin Chen

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(6), P. 401 - 401

Published: March 9, 2025

Ninjurin 1 and 2 (NINJ1, NINJ2) belong to the homophilic cell adhesion family play significant roles in cellular communication tissue development. While both NINJ1 NINJ2 are found be over-expressed several types of cancers, it remains unclear whether they can targeted for cancer treatment. In this study, we aimed develop NINJ1/2 peptides derived from N-terminal extracellular domain that elicit growth suppression thus possess therapeutic potentials. We peptide NINJ1-A, which is motif NINJ1, was able inhibit a NINJ1- or p53-dependent manner. Similarly, NINJ2-A, NINJ2, NINJ2- also physically interact via their respective domains. Interestingly, NINJ1-B NINJ2-B peptides, were amphipathic helix domains respectively, disrupt NINJ1-NINJ2 interaction NINJ1/NINJ2-dependent Notably, demonstrated greater potency than NINJ1-A NINJ2-A respectively. Mechanistically, induce p53 expression suppress Together, our findings provide valuable insights into development NINJ1/NINJ2 as potential therapeutics, particularly cancers harboring wild-type p53.

Language: Английский

Citations

0
Peptides in Breast Cancer Therapy: From Mechanisms to Emerging Drug Delivery and Immunotherapy Strategies DOI

Elmira Alaei,

Farid Hashemi,

Najma Farahani

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155946 - 155946

Published: March 1, 2025

Language: Английский

Citations

0